Mac Rabonik DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 40 mg, designed for the effective management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility by enhancing esophageal and gastric emptying and reducing symptoms such as nausea and vomiting. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, thereby providing symptomatic relief from acid-related irritation and promoting mucosal healing. The dual action of Mac Rabonik DSR Capsule addresses both the motility dysfunction and acid hypersecretion components of gastrointestinal pathology, offering improved symptom control and patient compliance. This combination is particularly beneficial in patients with GERD who exhibit delayed gastric emptying or persistent symptoms despite monotherapy. Mac Rabonik DSR Capsule should be administered as prescribed by a healthcare professional, with attention to contraindications such as hypersensitivity to either component, and caution in patients with underlying cardiac conditions due to Domperidone’s potential to prolong QT interval. Regular monitoring and adherence to recommended dosage enhance therapeutic outcomes and minimize adverse effects.